




# PHARMACEUTICAL 2020

ENDONOVO THERAPEUTICS INC.  
Rank 340 of 358





RealRate

# PHARMACEUTICAL 2020

## ENDONOVO THERAPEUTICS INC. Rank 340 of 358

The relative strengths and weaknesses of ENDONOVO THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDONOVO THERAPEUTICS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 105% points. The greatest weakness of ENDONOVO THERAPEUTICS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 247% points.

The company's Economic Capital Ratio, given in the ranking table, is -389%, being 425% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	63
Cost of Goods Sold	93
Intangible Assets	3,206
Liabilities, Current	23,623
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	4,026
Other Liabilities	155
Other Net Income	-13,505
Other Revenues	310
Property and Equipment	5.9
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	3,275
Liabilities	23,778
Expenses	4,119
Revenues	310
Stockholders Equity	-20,504
Net Income	-17,315
Comprehensive Net Income	-17,315
Economic Capital Ratio	-389%